SCHEMBL30775112

SCHEMBL30775112

CCn1cc(-c2ccn3c(-c4ccc(C#N)c(C)c4)cnc3c2)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 10/20 0.49
GABRA1 P14867 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRA2 P47869 1/20 0.44
EGLN2 Q96KS0 1/20 0.43
NEK2 P51955 5/20 0.41
AURKA O14965 2/20 0.41
ABL1 P00519 2/20 0.40
KDR P35968 1/20 0.40
PDGFRA P16234 1/20 0.40
CSK P41240 1/20 0.40
SIK1 P57059 1/20 0.40
IKBKE Q14164 1/20 0.40
SIK2 Q9H0K1 1/20 0.40
TBK1 Q9UHD2 1/20 0.40
TNIK Q9UKE5 1/20 0.40
SIK3 Q9Y2K2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27030611 1.00 FLT3 (0.49) FLT3GABRA1GABRG2GABRB3GABRA5
SCHEMBL25425217 0.88 FLT3 (0.50) FLT3NEK2AURKAABL1KDR
SCHEMBL27030692 0.83 FLT3 (0.47) FLT3NEK2AURKAABL1KDR
SCHEMBL27030682 0.78 FGFR3 (0.48) FLT3NEK2AURKAABL1KDR
SCHEMBL25425822 0.75 FLT3 (0.45) FLT3NEK2AURKAABL1KDR
SCHEMBL27030656 0.69 ALK (0.48) FLT3KDRFGFR3
SCHEMBL30441169 0.68 MKNK1 (0.44) FLT3EGLN2PIK3CA
SCHEMBL31501407 0.67 FLT3 (0.50) FLT3GABRA1GABRG2GABRB3GABRA5
SCHEMBL25605557 0.67 FLT3 (0.50) FLT3GABRA1GABRG2GABRB3GABRA5
SCHEMBL27030641 0.67 KDR (0.47) FLT3KDRFGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600719-B2 Salt inducible kinase inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2026-04-14 US disclosed
WO-2024233967-A2 SIK INHIBITORS TO TREAT CHRONIC KIDNEY DISEASE THE GENERAL HOSPITAL CORPORATION (US) 2024-11-14 WO disclosed
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12600719-B2 Salt inducible kinase inhibitors GRK6, SGK1, CSNK1A1 FLT3 2994/4885GABRA1 2275/4885GABRG2 2532/4885
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS SGK1, SGK2, SIK1 FLT3 1688/4885GABRA1 3498/4885GABRG2 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.